Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:39:26 23/01/2026 GMT			5-day change	1st Jan Change
44.56 ^EUR	+0.88%		+7.32%	+20.39%

01-23	BAYER AG : JP Morgan keeps its Buy rating	ZD
01-22	Bayer AG - FDA grants orphan drug designation to cell therapy OPCT-001	RE

Goldman Sachs Raises Bayer Price Target to EUR38.50, Maintains 'Buy' Rating

Published on 11/27/2025 at 07:19 am GMT - Modified on 11/27/2025 at 08:51 am GMT

dpa-AFX - Translated by Marketscreener - See original

BAYER AG

+0.88%

NEW YORK (dpa-AFX Broker) - U.S. investment bank Goldman Sachs has raised its price target for Bayer from EUR34.50 to EUR38.50 while maintaining its "Buy" rating. Following positive study results for the anticoagulant Asundexian, analyst James Quigley currently sees a favorable risk-reward profile ahead of upcoming news regarding the glyphosate litigation. According to Quigley, the outlook for the Leverkusen-based pharmaceutical division has significantly improved after the success of Asundexian in stroke prevention, as he wrote on Thursday./ag/tih

Original study publication: 27.11.2025 / 06:05 / CET

Initial distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------

Latest news about Bayer AG

01-23	BAYER AG : JP Morgan keeps its Buy rating	ZD
01-22	Bayer AG - FDA grants orphan drug designation to cell therapy OPCT-001	RE
01-22	DAVOS: Top Executive Fears Widening Economic Gap with the US	DP
01-21	AI company Eightfold sued for helping companies secretly score job seekers	RE
01-20	DAX Index Extends Losing Streak; German Economic Sentiment Improves	MT
01-20	Illumina Secures Reimbursement of Nearly $3,000 Per TruSight Test	MT
01-20	Bayer Partners with Vanderbilt on Cardiovascular and Kidney Disease Research	RE
01-20	Bayer Partners with US University Medical Center to Target Cardiovascular, Kidney Diseases	MT
01-20	Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases	CI
01-20	Bayer and Vanderbilt University Medical Center to advance treatments for cardiovascular and kidney diseases	RE
01-20	BAYER AG : Barclays remains its Buy rating	ZD
01-20	Germany's DAX Index Bleeds as Talks of US-Europe Trade War Reignites Over Greenland Threats	MT
01-19	Germany's DAX Index Bleeds as Talks of US-Europe Trade War Reignites Over Greenland Threats	MT
01-19	PI AgSciences Announces Leadership Changes for North America and Finance Organizations	CI
01-19	Global markets live: General Motors, Tesla, Micron, KKR, Bayer…
01-19	Mwb Keeps Bayer at Buy Amid "Clearer" Path to Roundup Litigation Resolution	MT
01-19	BAYER AG : DZ Bank keeps its Buy rating	ZD
01-19	DZ Bank Raises Bayer's Fair Value to 51 Euros - 'Buy'	DP
01-19	BAYER AG : Goldman Sachs gives a Buy rating	ZD
01-19	The Threat of a Trade War Dampens the Markets
01-19	European Midday Briefing : Shares Fall on Prospect of Renewed U.S. Trade Fight	DJ
01-19	Bayer Shares Surge as U.S. Supreme Court Agrees to Hear Glyphosate Case	DP
01-19	Bayer Shares Rise After U.S Supreme Court Agrees to Review Roundup Case	DJ
01-19	BAYER AG : UBS is Neutral	ZD
01-19	Bayer: US Supreme Court to Review Glyphosate Case, Shares Surge	DP

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release

More about the company